Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia

被引:19
作者
DeZern, Amy E. [1 ]
Brodsky, Robert A. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Hematol Malignancies, 1650 Orleans St,CRBI Room 3M87, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Div Hematol, 720 Rutland Ave,Ross 1025, Baltimore, MD 21205 USA
关键词
Severe aplastic anemia; Cyclophosphamide; Haploidentical transplant; Graft versus host disease; STEM-CELL TRANSPLANTATION; HIGH-DOSE CYCLOPHOSPHAMIDE; VERSUS-HOST-DISEASE; ANTI-HLA ANTIBODIES; TERM-FOLLOW-UP; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE THERAPY; PERIPHERAL-BLOOD; ANTITHYMOCYTE GLOBULIN; PEDIATRIC-PATIENTS;
D O I
10.1016/j.hoc.2018.04.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hematopoietic stem cell transplantation (bone marrow transplantation [BMT]) is the only curative treatment of severe aplastic anemia. BMT from a human leukocyte antigen (HLA)-matched sibling donor is the standard of care for young patients; immunosuppressive therapy is used for older patients or those lacking matched sibling donors. Patients with refractory or relapsed disease are increasingly treated with HLA haploidentical BMT. Historically, haploidentical BMT led to high rates of graft rejection and graft-versus-host disease. High-dose posttransplant cyclophosphamide, which mitigates the risk of graft-versus-host disease, is a major advance. This article provides an overview of the haploidentical BMT approach in severe aplastic anemia.
引用
收藏
页码:629 / +
页数:15
相关论文
共 67 条
[1]  
Alter Blanche P, 2007, Hematology Am Soc Hematol Educ Program, P29, DOI 10.1182/asheducation-2007.1.29
[2]   Bone marrow failure syndromes in children [J].
Alter, BP .
PEDIATRIC CLINICS OF NORTH AMERICA, 2002, 49 (05) :973-+
[3]  
[Anonymous], [No title captured]
[4]   Treatment of acquired severe aplastic anemia:: Bone marrow transplantation compared with immunosuppressive therapy -: The European Group for Blood and Marrow Transplantation Experience [J].
Bacigalupo, A ;
Brand, R ;
Oneto, R ;
Bruno, B ;
Socié, G ;
Passweg, J ;
Locasciulli, A ;
Van Lint, MT ;
Tichelli, A ;
McCann, S ;
Marsh, J ;
Ljungman, P ;
Hows, J ;
Marin, P ;
Schrezenmeier, H .
SEMINARS IN HEMATOLOGY, 2000, 37 (01) :69-80
[5]   Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? [J].
Bacigalupo, Andrea .
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2012, :223-229
[6]   Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups [J].
Bacigalupo, Andrea ;
Socie, Gerard ;
Schrezenmeier, Hubert ;
Tichelli, Andre ;
Locasciulli, Anna ;
Fuehrer, Monika ;
Risitano, Antonio M. ;
Dufour, Carlo ;
Passweg, Jakob R. ;
Oneto, Rosi ;
Aljurf, Mahmoud ;
Flynn, Catherine ;
Mialou, Valerie ;
Hamladji, Rose Marie ;
Marsh, Judith C. W. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08) :1142-1148
[7]   HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease [J].
Bolanos-Meade, Javier ;
Fuchs, Ephraim J. ;
Luznik, Leo ;
Lanzkron, Sophie M. ;
Gamper, Christopher J. ;
Jones, Richard J. ;
Brodsky, Robert A. .
BLOOD, 2012, 120 (22) :4285-4291
[8]   Aplastic anaemia [J].
Brodsky, RA ;
Jones, RJ .
LANCET, 2005, 365 (9471) :1647-1656
[9]   Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia [J].
Brodsky, RA ;
Sensenbrenner, LL ;
Smith, BD ;
Dorr, D ;
Seaman, PJ ;
Lee, SM ;
Karp, JE ;
Brodsky, I ;
Jones, RJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (07) :477-483
[10]   High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up [J].
Brodsky, Robert A. ;
Chen, Allen R. ;
Dorr, Donna ;
Fuchs, Ephraim J. ;
Huff, Carol Ann ;
Luznik, Leo ;
Smith, B. Douglas ;
Matsui, William H. ;
Goodman, Steven N. ;
Ambinder, Richard F. ;
Jones, Richard J. .
BLOOD, 2010, 115 (11) :2136-2141